Background: Feline herpesvirus-1 (FHV-1) infection can result in serious morbidity and mortality,
| INTRODUCTION
Feline herpesvirus 1 (FHV-1) is a common cause of ocular and upper respiratory infections in cats and can be a major cause of morbidity and sometimes mortality, especially in young kittens. [1] [2] [3] [4] [5] Prior administration of FHV-1 vaccines may lessen illness if exposed, but vaccination against FHV-1 provides incomplete immunity. [6] [7] [8] [9] Clinical signs of FHV-1 infection can be reactivated with repeat exposure, after induction of stress, or after administration of immunosuppressive drugs. [10] [11] [12] One study showed that after FHV-1 challenge, a significant decrease in clinical scores was noted in kittens as soon as 4 days after administration of 1 dose of an intranasal vaccine, and this decrease occurred before development of specific FHV-1 immune responses. 7 Administration of an intranasal FHV-1 vaccine was shown to induce cross protection against Bordetella bronchiseptica, a primary bacterial pathogen in cats that was not contained in the vaccine. 13 These
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findings suggested that intranasal administration of these 2 vaccines had induced nonspecific immune responses that imparted a positive effect against the primary pathogen. This result supports continued work to evaluate stimulation of innate immunity for protection against infections in cats.
Toll-like receptors are evolutionarily conserved receptors that activate cellular immune defenses against a variety of different pathogens. [14] [15] [16] Viruses and bacteria express specific molecular structures that are capable of activating toll-like receptors 3 (TLR3) and TLR9, respectively. [14] [15] [16] Given that TLR activation can generate nonspecific protection from infections, several different approaches to developing immunotherapeutic agents that activate TLR pathways have been developed for generating protective immunity. One widely studied immunotherapy platform is based on triggering innate immune responses using TLR9 agonists complexed to cationic liposomes, which greatly enhances the activity of the TLR9 agonist. 17, 18 In a number of animal challenge studies, parenteral or inhalational administration of liposomal-TLR9 complexes generated complete or nearly complete protection against highly virulent bacterial and viral pathogens. [19] [20] [21] [22] [23] [24] In addition, administration of liposome-TLR9
complexes to cats with chronic rhinitis also was shown to alleviate some clinical signs of illness. 25 Recently, a new formulation of a liposome-TLR complex (LTC)
was developed that includes a TLR9 agonist, a TLR3 agonist, and methylcellulose as a mucosal adhesive agent. 26 In a study of healthy, purpose-bred cats, cytokine and cellular immune responses to this LTC were evaluated in vitro and in vivo. Quantitative polymerase chain reaction (qPCR) assays, ELISA assays, and flow cytometry were used to evaluate nasal lavage specimens and pharyngeal swabs. 26 In that study, the in vitro experiment showed that the LTC rapidly activated cat leukocytes, including upregulation of costimulatory molecules and cytokine production. The in vivo experiment showed that topical administration of the LTC triggered rapid recruitment of monocytes to the nasal and oropharyngeal mucosa in the healthy cats.
Based on the results from these in vivo and in vitro experiments in healthy cats, the objective of our pilot study was to determine whether mucosal administration of LTC before FHV-1 challenge could decrease the severity of clinical signs, hasten resolution of clinical signs, and decrease FHV-1 DNA shedding in the kittens. Our primary hypothesis was that administration of LTC before FHV-1 challenge would induce positive clinical outcomes to infection.
| MATERIALS AND METHODS

| Animals
Nine female and 10 male, 14-week old, purpose-bred nonvaccinated domestic shorthair kittens were included in this 28-day pilot study.
Before the start of the study, all kittens were serologically negative for FHV-1, and pharyngeal swab samples obtained from each kitten were negative for DNA of FHV-1 by PCR assay (Center for Companion Animal Studies, Colorado State University, Fort Collins, Colorado).
Before the start of the study, gonadectomies were performed in each of the males (19 days) and 6 randomly selected females (26 days). 
| LTC formulation
| Study design
The 19 study animals were divided into 2 separate rooms that varied in size with the smaller room housing the LTC group (n = 7; 3 intact females and 4 neutered males) and the larger room housing the untreated control group (n = 12; 6 neutered females and 6 neutered males). The dissimilar group sizes and rooms were used because of a previously planned study that included the 12 control cats. 11 The kittens were housed and cared for in accordance with a protocol approved by the Institutional Animal Care and Use Committee at the contract research facility.
Five days before the start of the study, the kittens were moved into their respective rooms. Twenty-four hours before FHV-1 inoculation, the kittens in the LTC group were given 0. (Table 1) . 9, 10 Body temperatures were determined by microchip. 27 Increased body temperature was defined as >102. 
| Laboratory evaluations
On Days 7, 14, 21, and 28, mucosal cells were collected from the caudal pharynx of each kitten using manual restraint without sedation.
Swabs were stored at −80 C until assayed in batches. Total DNA was extracted from the oropharyngeal swabs and evaluated for DNA of FHV-1, DNA of the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene, and feline 28S ribosomal DNA by qPCR as previously described. 28, 29 Results of the FHV-1 qPCR assay were expressed as the ratio of FHV-1 DNA/GAPDH DNA in an attempt to standardize specimens and ensure sample adequacy by presence of GAPDH in the sample. To verify findings between groups of cats using the FHV-1/ GAPDH ratio calculation, the delta-delta Cq method was used to compare FHV-1 to 28S results and then compared between groups in the statistical analyses. 30 
| Statistical analysis
Soon after the FHV-1 challenge and onset of clinical signs in study animals, it was determined that sneezing and nasal congestion were being underestimated in the control group because of the larger number of kittens (n = 12). Thus, the scorers were unable to reliably capture sneezing and nasal discharge occurrences in the larger study group. Sneezing and nasal congestion therefore were excluded from all subsequent data analyses.
Three time periods were used for data analysis: Days 1-14, 15-28, and 1-28. Observation occurrences were defined as the number of times a clinical sign (Table 1) used for all comparisons. Significance was defined as P < .05. (P = .07). On Day 28 of the study, the group median body weight had increased more for the LTC group than for the control group, but the difference was not statistically significant (P = .08).
| RESULTS
| Clinical findings
Conjunctivitis scores ≥1 were detected more frequently in the control group when compared to the LTC group on Days 1-14 (30% versus 16%; P = .01), Days 15-28 (29% versus 10%; P < .001), and Days 1-28 (29.5% vs 13%; P < .001). After controlling for lack of independence because of repeated measurements on the same kitten over time (Figure 1 ), the odds of having conjunctivitis were greater among kittens in the control group as compared to kittens in the LTC group on Days 15-28 (OR, 4.4; 95% CI, 1.4-14; P = .01) and Days 1-28 (OR 3.1; 95% CI, 1.2-7.6; P = .02).
Total respiratory scores were higher in the LTC group compared to the control group on Days 15-28 (P < .001) and Days 1-28 (P < .001).
After controlling for lack of independence, total respiratory scores were higher in the LTC group when compared to the control group on 
| FHV-1/GAPDH ratios and FHV-1 to 28S results
Detectable FHV-1/GAPDH ratios >0 were detected on at least 3 of the 4 dates of sample collection for 6 kittens in the LTC group and all 12 kittens in the control group. The largest amount of FHV-1 DNA was recovered on Day 7 for all kittens. The amount of FHV-1 DNA recovered was significantly higher in the control group on Day 21 (P = .04), Day 28 (P = .002), and when results from Days 21 and 28 were combined (P = .001). A total of 71 swabs (26 from the LTC group and 45 from the control group) contained quantifiable GAPDH and thus were used in this analysis. The FHV-1/GAPDH ratios did not differ between the groups on Days 7, 14, and 28 ( Figure 2 ). On Day 21, the control group had significantly higher FHV-1/GAPDH ratios as compared to the LTC group (P = .04). When the results from Days 21 and 28 were combined, the control group had significantly higher FHV-1/GAPDH ratios as compared to the LTC group (P = .01; Figure 2 ). When the analyses were repeated using results of the FHV-1 to 28S calculation to verify the results from the FHV-1/GAPDH ratios (data not shown), the control group was significantly higher as compared to the LTC group on Day 28 (P = .001) and when the results from Days 21 and 28 were combined (P = 0.005).
| DISCUSSION
All kittens in the study experienced acute clinical signs of FHV-1 infection, and all had measurable shedding of FHV-1 DNA documenting induction of FHV-1 infection. Our findings documenting an LTC and stimulation of NK cell activation and proliferation. 17, 19, 21, 22 The TLR3 pathway in particular is important in innate immune defense against viral infections. 32 For example, it also has been shown that deficiency of TLR3 in humans can be associated with susceptibility to herpes simplex virus 1 encephalitis. 33 When normal cats were given LTC, most of the immunological effects were noted within hours to days after administration. 26 In the study described here, however, significant decreases in FHV-1 DNA shedding and some clinical abnormalities (especially ocular signs) suggest a delayed effect induced by LTC. These findings also may relate to the large infective dose of FHV-1 administered to the kittens, because a higher infective dose is associated with a longer duration of viral excretion. 34 In future studies, a natural model of infection may show different magnitude and timing of potential treatment effects. One of the primary limitations of our study was unequal group sizes and differences in the size of the evaluation rooms. These inequalities confounded the ability of the clinical observers to record sneezing and nasal congestion variables accurately. Sneezing is 1 of the most objective and quantifiable respiratory clinical signs of FHV-1 infection and should be included in the analyses in future studies. 11 Another potential limitation was to have all 3 intact females assigned to the LTC group.
Although all kittens were sexually immature at the time of the study, the effects of early gonad removal on immune function are unknown, especially in prepubescent animals. Future studies should ensure more equal distributions between groups. Lastly, although GAPDH has been used successfully as a comparison gene in other published FHV-1 treatment studies in cats 1, 11, 28 and the findings were similar between the FHV-1/GAPDH and FHV-1 to 28S calculations using the data described here, it is possible that the use of multiple comparison genes simultaneously could provide additional information or different results. FHV-1 and other pathogens and where transmission is by more natural routes and doses of the agents.
